Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 6 SUPPL. 1, 2008, Pages 8-21

  Poynard, T ^a   Muntenau, M ^b   Morra, R ^a   Ngo, Y ^a   Imbert Bismut, F ^a   Thabut, D ^a   Messous, D ^a   Massard, J ^a   Lebray, P ^a   Moussalli, J ^a   Benhamou, Y ^a   Ratziu, V ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Biopredictive   (France)

Author keywords

biomarkers; Cirrhosis; FibroMeters; FibroTest; Liver fibrosis; non invasive

Indexed keywords

ADEFOVIR; BIOLOGICAL MARKER;

ARTICLE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; PROGNOSIS;

BIOLOGICAL MARKERS; BIOPSY; HUMANS; LIVER CIRRHOSIS;

EID: 54349094241     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(08)73990-3     Document Type: Article

References (60)

1. Bravo A.A., Sheth S.G., and Chopra S. Liver biopsy. N Engl J Med 344 (2001) 495-500
2. Bedossa P., Dargère D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
3. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
4. Bedossa P., Poynard T., Naveau S., Martin E.D., Agostini H., and Chaput J.C. Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol Clin Exp Res 12 (1988) 173-178
5. McHutchison J., Poynard T., and Afdhal N. International Fibrosis Group Meeting Participants. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol 4 (2006) 1214-1220
6. Poynard T., Ratziu V., and Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 14 (2000) 543-548
7. Sebastiani G., and Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 21 12 (2006) 3682-3694
8. Poynard T., Ratziu V., Benhamou Y., Thabut D., and Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?. Gastroenterology 128 (2005) 1146-1148
9. Manning D.S., and Afdhal N.H. Diagnosis and quantitation of fibrosis. Gastroenterology 134 (2008) 1670-1681
10. Castera L., Denis J., Babany G., and Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new guidelines?. J Hepatol 46 (2007) 528-529
11. Fontaine H., Petitprez K., Roudot-Thoraval F., and Trinchet J.C. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 31 (2007) 504-509
12. Poynard T., Imbert-Bismut F., Munteanu M., Messous D., Myers R.P., Thabut D., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV-Fibrosure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3 (2004) 8
13. Poynard T., Imbert-Bismut F., Munteanu M., and Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?. Expert Rev Mol Diagn. 5 (2005) 15-21
14. Morra R., Munteanu M., Imbert-Bismut F., Messous D., Ratziu V., and Poynard T. FibroMAX: towards a new universal biomarker of liver disease?. Expert Rev Mol Diagn. 7 (2007) 481-490
15. Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert-Bismut F., et al. Meta-analyses of Fibrotest diagnostic value in chronic liver disease. BMC Gastroenterology 7 (2007) 40
16. Poynard T., Morra R., Ingiliz P., Imbert-Bismut F., Thabut D., Messous D., et al. Biomarkers of liver fibrosis. Adv Clin Chem 46 (2008) 131-152
17. Halfon P., Munteanu M., and Poynard T. Fibrotest-Actitest as a non invasive marker of liver Fibrosis seven years ago: a 2008 updated meta-analyses of FT diagnostic and prognostic values in chronic liver diseases. Gastroenterol Clin Biol 32 (2008) à completer
18. Ransohoff D.F., and Feinstein A.R. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 299 (1978) 926-930
19. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Radiol 58 (2003) 575-580
20. Poynard T. Evaluation of diagnostic methods. Application to the diagnosis of benign or malignant colonic tumours. Nouv Presse Med. 7 (1978) 2031-2033
21. Poynard T., Halfon P., Castera L., Charlotte F., Bail B.L., Munteanu M., et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther. 25 (2007) 733-739
22. Poynard T., Halfon P., Castera L., Munteanu M., Imbert-Bismut F., Ratziu V., et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem. 53 (2007) 1615-1622
23. Poynard T., Munteanu M., Ngo Y., Moussalli J., Lebray P., Thabut D., et al. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence. J Viral Hepat. 15 (2008) 472-473
24. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
25. Gebo K.A., Herlong H.F., Torbenson M.S., Jenckes M.W., Chander G., Ghanem K.G., et al. Role of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology 36 (2002) S161-S172
26. Bissell D.M. Assessing fibrosis without a liver biopsy: are we there yet?. Gastroenterology 127 (2004) 1847-1849
27. Lackner C., Struber G., Liegl B., Leibl S., Ofner P., Bankuti C., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41 (2005) 1376-1382
28. Rockey D.C., and Bissell D.M. Noninvasive measures of liver fibrosis. Hepatology 43 (2006) S113-S120
29. Parkes J., Indra Neil Guha I.N., Roderick P., and Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 44 (2006) 462-474
30. Hui S.L., and Zhou X.H. Evaluation of diagnostic tests without gold standards. Statistical Methods in Medical Research 7 (1998) 354-370
31. Lambert J., Halfon P., Penaranda G., Bedossa P., Cacoub P., and Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 54 (2008) 1372-1378
32. Obuchowski N.A. An ROC-type measure of diagnostic accuracy when the gold standard is continuous-scale. Stat Med. 25 (2006) 481-493
33. Baker S.G. Evaluating multiple diagnostic tests with partial verification. Biometrics 51 (1995) 30-37
34. Shaheen A.A., and Myers R.P. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 46 (2007) 912-921
35. Morra R., Lebray P., Ingiliz P., Ngo Y., Munteanu M., Ratziu V., et al. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. Hepatology 47 (2008) 353
36. Poynard T., Munteanu M., Imbert-Bismut F., Charlotte F., Thabut D., Le Calvez S., et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic Hepatitis C. Clin Chem 50 (2004) 1344-1355
37. Poynard T., McHutchison J., Manns M., Myers R.P., and Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 38 (2003) 481-492
38. Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by Hepatitis B Virus. J Vir Hep 2008; in press
39. Ngo Y., Munteanu M., Messous D., Charlotte F., Imbert-Bismut F., Thabut D., et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem. 52 (2006) 1887-1896
40. Ngo Y., Benhamou Y., Thibault V., Ingiliz P., Munteanu M., Lebray P., et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (Fibrotest-Actitest) and viral load. PlosOne 3 (2008) e2573
41. Mehta P., Ploutz-Snyder R., Nandi J., Rawlins S.R., Sanderson S.O., and Levine R.A. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 103 (2008) 928-936
42. Guha I.N., Parkes J., Roderick P., Chattopadhyay D., Cross R., Harris S., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47 (2008) 455-460
43. Patel K., Nelson D.R., Rockey D.C., Afdhal N.H., Smith K.M., Oh E., et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol 6 (2008) 242-247
44. Cacoub P., Carrat F., Bedossa P., Lambert J., Pénaranda G., Perronne C., et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The Fibrovic study - ANRS HC02. J Hepatol 48 (2008) 765-773
45. Poynard T., Bedossa P., Opolon P., and Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
46. Poynard T., Mathurin P., Lai C.L., Guyader D., Poupon R., Tainturier M.H., et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38 (2003) 257-265
47. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis inpatients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
48. Poynard T. Uses of error. Lancet 359 (2002) 1514
49. Poynard T. Faut-il encore faire des biopsies du foie?. Rev Med Interne 28 (2007) 67-70
50. Poynard T., Aubert A., Bedossa P., Abella A., Naveau S., Paraf F., et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 100 (1991) 1397-1402
51. Imbert-Bismut F., Ratziu V., Laurence Pieroni L., Charlotte F., Benhamou Y., Poynard T., et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
52. Mehta SH, Lau B, Afdahl NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2008 in press.
53. Ferard G., Imbert-Bismut F., Messous D., Piton A., Ueda S., Poynard T., et al. A reference material for traceability of aspartate aminotransferase (AST) results. Clin Chem Lab Med. 43 (2005) 549-553
54. Piton A., Poynard T., Imbert-Bismut F., Khalil L., Delattre J., Pelissier E., et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 27 (1998) 1213-1219
55. Poynard T., Munteanu M., Ngo Y., Moussalli J., Lebray P., Thabut D., et al. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence. J Viral Hepat. 15 (2008) 472-473
56. Jacqueminet S., Lebray P., Morra R., Munteanu M., Devers L., Messous D., et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol 6 (2008) 828-831
57. Thabut D., Le Calvez S., Thibault V., Massard J., Munteanu M., Di Martino V., et al. Hepatitis C in 6,865 Patients 65 yr or Older: A severe and neglected curable disease?. Am J Gastroenterol 101 (2006) 1260-1267
58. Roulot D., Czernichow S., Le Clésiau H., Costes J.L., Vergnaud A.C., and Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 48 (2008) 606-613
59. Castéra L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005) 343-350
60. FDA. Draft Guidance for Industry, Clinical Laboratories, and FDA Staff In Vitro Diagnostic Multivariate Index Assays. www.fda.gov/cdrh/oivd/guidance/1610.pdf. Connected July 2008.